Group 1 - The core viewpoint of the report is that Hongbo Pharmaceutical (301230.SZ) is rated as "Buy" due to its strong Q3 revenue growth and rapid profit recovery year-on-year [1] - The report highlights a significant improvement in profit margins year-on-year, along with optimized sales and R&D expense ratios [1] - There is a gradual recovery in overseas demand, and the company is entering a phase of rapid volume growth [1]

Core Viewpoint - The company reported strong revenue growth and significant profit recovery in the third quarter of 2025, driven by the gradual recovery of overseas demand and optimized cost management [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 514 million, a year-on-year increase of 31.43%, and a net profit attributable to shareholders of 35 million, up 127.96%. The net profit after deducting non-recurring items was 28 million, reflecting a growth of 353.43% [1]. - In Q3 2025, the company recorded revenue of 162 million, a year-on-year growth of 28.67%, and a net profit of 9.99 million, marking a turnaround from loss to profit compared to the same period last year [2]. Profitability Metrics - The gross margin for the first three quarters of 2025 was 28.05%, an increase of 4.29 percentage points year-on-year, while the net margin was 6.76%, up 2.87 percentage points [2]. - The company optimized its sales and R&D expense ratios, which were 1.90% and 5.60% respectively, down 0.56 and 3.57 percentage points from the previous year [2]. Market Outlook - The company anticipates a recovery in overseas business due to the easing of monetary policy by the Federal Reserve and a rebound in overseas investment and demand [2]. - The commercial production business is expected to enter a rapid growth phase following the expiration of patent protection for a key product in December 2024, leading to increased overseas demand [2]. Earnings Forecast - Revenue projections for 2025-2027 are 739 million, 989 million, and 1.299 billion, with year-on-year growth rates of 35.79%, 33.79%, and 31.34% respectively. Net profits are forecasted at 47 million, 64 million, and 99 million, corresponding to PE ratios of 100, 72, and 47 [3].

证券代码：301230 证券简称：泓博医药 公告编号：2025-062 上海泓博智源医药股份有限公司 关于实际控制人一致行动关系续期及间接控股股东部分上层股东 表决权委托续期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海泓博智源医药股份有限公司（以下简称"公司"）实际控制人 Ping Chen 先生、 安荣昌先生、蒋胜力先生（以下简称"各方"）签署的《一致行动人协议之补充协议》 于 2025 年 10 月 31 日到期。同时，公司间接控股股东 PharmaResources Holding Co.,Ltd. （以下简称"泓博控股"）之股东 Hongjian Zhang、MICHAEL GAO、Genesis Ventures Investments Limited（以下简称"Genesis"）与 Ping Chen 先生之间的关于泓博控股的表 决权委托关系亦于 2025 年 10 月 31 日到期。 基于对公司长远发展的信心，同时为保障公司持续、稳定发展，提高公司经营决策 效率，各方于 2025 年 10 月 31 日签署了《一致行动人协议之补充 ...

Core Insights - The company has demonstrated significant performance improvement in the first three quarters of 2025, showcasing strong development momentum and market competitiveness [1][2] Financial Performance - The company achieved a total revenue of 514 million yuan in the first three quarters, representing a year-on-year growth of 31.43% [1] - The net profit attributable to shareholders reached 34.75 million yuan, with a remarkable year-on-year increase of 127.96%, indicating a substantial enhancement in profitability [1] - In the third quarter alone, the company generated revenue of 162 million yuan, reflecting a year-on-year growth of 28.67%, and net profit of 9.99 million yuan, successfully turning around from a loss [1] Business Operations - As a comprehensive pharmaceutical research and production enterprise, the company covers various aspects including drug discovery, pharmaceutical process research and development, and commercial production [1] - The company has increased its R&D investment, leveraging the advantages of its CADD/AIDD and DiOrion platforms to enhance new drug development efficiency and shorten development cycles [1] Strategic Initiatives - The new equity incentive plan has been successfully implemented, effectively stimulating the enthusiasm and creativity of the core team and employees [1] - The company is actively expanding its domestic and international markets, establishing strategic partnerships with several internationally renowned pharmaceutical companies, thereby enhancing its brand influence and market competitiveness [1] Future Outlook - The company plans to continue its innovation-driven development strategy, increasing technical investment in new drug research and development to enhance its comprehensive service capabilities [2] - With the steady growth of the global pharmaceutical market and the deepening of the company's business layout, there is potential for broader development opportunities, creating long-term value for shareholders and society [2]

证券代码：301230 证券简称：泓博医药 公告编号：2025-061 上海泓博智源医药股份有限公司 关于首次公开发行前已发行股份解除限售并上市流通 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为上海泓博智源医药股份有限公司（以下简称"公司"） 首次公开发行前已发行的股份； 2、本次解除限售股东户数共计 4 户，解除限售股份数量为 62,726,300 股，占公司总 股本的 44.9372%。限售期为自公司股票首次公开发行并上市之日起 36 个月； 3、本次解除限售股份上市流通日期为 2025 年 11 月 1 日（星期六），因该日为非交 易日，故上市流通日顺延至下一交易日 2025 年 11 月 3 日（星期一）。 一、首次公开发行股票及上市后股本和限售股变动情况 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意上海泓博智源医药股份有限公司首次公开发行 股票注册的批复》（证监许可[2022]1443 号）同意注册，公司首次公开发行人民币普通股 （A 股）股票已于 2022 年 11 月 1 日 ...

中信证券股份有限公司 关于上海泓博智源医药股份有限公司 首次公开发行前已发行部分股份上市流通的核查意见 4、公司于 2024 年 5 月 15 日召开公司 2023 年年度股东大会，审议通过了《关 于公司 2023 年度利润分配方案的议案》，拟以实施利润分配方案时股权登记日 已发行总股本扣除回购股份数为基数，进行资本公积转增股本，每 10 股转增 3 股。2024 年 6 月 21 日，上述权益分派实施完成，转增后公司总股本增至 139,586,605 股。 （三）本次限售股份解除限售情况 截至本核查意见出具日，公司总股本为 139,586,605 股，其中无流通限制或 限售安排的股票数量为 76,860,305 股，占公司总股本的比例为 55.0628%；有流 通限制及限售安排的股票数量为 62,726,300 股，占公司总股本的比例为 44.9372%。 本次上市流通的限售股属于首次公开发行前已发行股份，锁定期为自公司首次公 开发行并上市之日起 36 个月，股份数量为 62,726,300 股，占公司总股本比例的 44.9372%，该股份的锁定期将于 2025 年 10 月 31 日届满，将于 2025 ...

Core Viewpoint - Hongbo Pharmaceutical (301230.SZ) reported significant growth in revenue and net profit for the first three quarters of 2025, indicating strong operational performance and potential investment opportunities [1] Financial Performance - The company achieved a revenue of 514 million yuan, representing a year-on-year increase of 31.43% [1] - The net profit attributable to shareholders reached 34.75 million yuan, marking a year-on-year increase of 127.96% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 27.71 million yuan, reflecting a substantial year-on-year increase of 353.43% [1] - Basic earnings per share stood at 0.2489 yuan [1]

Core Viewpoint - Hongbo Pharmaceutical (301230.SZ) reported a significant increase in revenue and net profit for the first three quarters of 2025, indicating strong business performance and growth potential [1] Financial Performance - The company's operating revenue for the first three quarters reached 514 million yuan, representing a year-on-year growth of 31.43% [1] - The net profit attributable to shareholders of the listed company was 34.75 million yuan, showing a year-on-year increase of 127.96% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 27.71 million yuan, reflecting a substantial year-on-year growth of 353.43% [1] - Basic earnings per share stood at 0.2489 yuan [1]

上海泓博智源医药股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 证券代码：301230 证券简称：泓博医药 公告编号：2025-060 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、行政法规、部 门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 14 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 14 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 11 月 14 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：20 ...

证券代码：301230 证券简称：泓博医药 公告编号：2025-058 上海泓博智源医药股份有限公司 第四届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 本议案经公司第四届董事会审计委员会审议通过。 一、董事会会议召开情况 上海泓博智源医药股份有限公司（以下简称"公司"）第四届董事会第五次会议通 知于2025年10月22日以邮件的形式送达全体董事。会议于2025年10月28日上午10:00 在上海市浦东新区凯庆路 59 号 12 幢二楼公司会议室以现场结合通讯表决的方式召开。 会议应出席董事 7 名，实际出席 7 名。本次会议由董事长 Ping Chen 博士主持召开，公司 高级管理人员列席了会议。会议召开及表决程序符合《中华人民共和国公司法》及《上海 泓博智源医药股份有限公司章程》的有关规定。 二、董事会会议审议情况 经出席会议的全体董事认真审议，通过了如下议案： 1、审议通过《关于<2025 年第三季度报告>的议案》 董事认真审议了公司 2025 年第三季度报告，认为公司第三 ...